# Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

> **NCT04549597** · PHASE4 · COMPLETED · sponsor: **Ardelyx** · enrollment: 333 (actual)

## Conditions studied

- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia

## Interventions

- **DRUG:** Tenapanor

## Key facts

- **NCT ID:** NCT04549597
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-20
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-12-01
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04549597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04549597, "Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04549597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*